The National Comprehensive Cancer Network has implemented categories of preference for recommendations within their clinical practice guidelines in oncology. READ MORE

Author Insights

Recent research has uncovered a non-inferior, cost-effective alternative to standard therapy for autologous stem cell mobilization in multiple myeloma. The study’s author discusses his findings.

READ MORE

News

Daratumumab-based combination therapies are ineffective in patients with multiple myeloma who have been heavily pre-treated or are refractory to one or more agents in a DCT.

READ MORE

Lenalidomide maintenance therapy after autologous stem-cell transplantation prolongs the time to remission in patients with multiple myeloma.

READ MORE

Lenalidomide plus dexamethasone more effectively treats newly diagnosed multiple myeloma patients ineligible for stem-cell transplantation, regardless of age, than a triplet of older drugs.

READ MORE

Early treatment with lenalidomide plus dexamethasone delays time to progression in some high-risk patients with smoldering multiple myeloma.

READ MORE

Resources

The National Comprehensive Cancer Network has implemented categories of preference for recommendations within their clinical practice guidelines in oncology.

READ MORE